HK Stock MarketDetailed Quotes

06660 AIM VACCINE

Watchlist

8.090
+0.300+3.85%

Not Open Nov 12 16:08 CST

9.80BMarket Cap-7511P/E (TTM)

AIM VACCINE Key Stats

Cash Flow

All

YOY

Hide blank lines

(Q6)Jun 30, 2024

(FY)Dec 31, 2023

(Q6)Jun 30, 2023

(FY)Dec 31, 2022

(FY)Dec 31, 2021

(Q6)Jun 30, 2021

(FY)Dec 31, 2020

(Q6)Jun 30, 2020

(FY)Dec 31, 2019

(FY)Dec 31, 2018

Turnover

-0.61%537.18M

-6.06%1.19B

--540.47M

-19.49%1.26B

-4.14%1.57B

26.53%672.56M

72.12%1.64B

--531.56M

-14.36%951.65M

--1.11B

Operating income

-0.61%537.18M

-6.06%1.19B

540.47M

-19.49%1.26B

-4.14%1.57B

26.53%672.56M

72.12%1.64B

531.56M

-14.36%951.65M

1.11B

Cost of sales

-38.09%-148.89M

-21.17%-286.45M

---107.82M

14.17%-236.41M

2.98%-275.43M

-16.74%-124.08M

-29.74%-283.88M

---106.29M

10.69%-218.8M

---244.98M

Operating expenses

-38.09%-148.89M

-21.17%-286.45M

-107.82M

14.17%-236.41M

2.98%-275.43M

-16.74%-124.08M

-29.74%-283.88M

-106.29M

10.69%-218.8M

-244.98M

Gross profit

-10.25%388.29M

-12.32%901.02M

432.65M

-20.63%1.03B

-4.39%1.29B

28.97%548.48M

84.77%1.35B

425.27M

-15.39%732.85M

866.19M

Selling expenses

-3.26%-232.24M

-0.17%-494M

---224.9M

-7.18%-493.17M

13.71%-460.11M

-29.33%-228.83M

-61.59%-533.25M

---176.94M

30.48%-330.01M

---474.71M

Administrative expenses

-7.35%-124.16M

43.59%-254.29M

---115.66M

61.41%-450.76M

-487.82%-1.17B

-1,049.55%-1.03B

-26.41%-198.7M

---89.23M

16.48%-157.18M

---188.19M

Research and development expenses

57.32%-170.11M

-27.20%-636.4M

---398.53M

-62.78%-500.31M

-94.82%-307.35M

-202.11%-139.61M

-59.54%-157.76M

---46.21M

-76.10%-98.89M

---56.15M

Impairment and provision

-5.10%-3.86M

-6,473.38%-1.79B

---3.67M

-241.00%-27.22M

-866.22%-7.98M

-64.36%-2.5M

-139.28%-826K

---1.52M

117.82%2.1M

---11.8M

-Impairment of intangible assets

----

---1.51B

----

-Impairment of property, machinery and equipment

----

---61.09M

----

-Goodwill impairment

----

---211.44M

----

-Other impairment is provision

-5.10%-3.86M

84.64%-4.18M

---3.67M

-241.00%-27.22M

-866.22%-7.98M

-64.36%-2.5M

-139.28%-826K

---1.52M

117.82%2.1M

---11.8M

Special items of operating profit

-34.15%12.77M

29.69%45.8M

--19.39M

-33.02%35.32M

38.49%52.73M

126.16%25.09M

103.92%38.07M

--11.09M

50.19%18.67M

--12.43M

Operating profit

55.52%-129.31M

-445.16%-2.23B

-290.72M

31.46%-408.47M

-218.81%-596M

-772.10%-823.11M

199.40%501.63M

122.47M

13.38%167.54M

147.77M

Financing cost

-56.60%-30M

-70.60%-43.83M

---19.16M

-140.05%-25.69M

32.01%-10.7M

46.05%-5.41M

-46.01%-15.74M

---10.04M

-47.28%-10.78M

---7.32M

Earning before tax

48.59%-159.31M

-422.99%-2.27B

-309.88M

28.44%-434.17M

-224.87%-606.7M

-836.91%-828.53M

209.95%485.89M

112.43M

11.61%156.76M

140.45M

Tax

-73.22%14.05M

57.42%320.4M

--52.45M

394.25%203.54M

19.07%-69.17M

-45.23%-34.77M

-131.34%-85.47M

---23.94M

5.34%-36.95M

---39.03M

After-tax profit from continuing operations

43.57%-145.26M

-745.61%-1.95B

-257.43M

65.88%-230.63M

-268.79%-675.87M

-1,075.54%-863.29M

234.20%400.41M

88.49M

18.14%119.81M

101.42M

Earning after tax

43.57%-145.26M

-745.61%-1.95B

-257.43M

65.88%-230.63M

-268.79%-675.87M

-1,075.54%-863.29M

234.20%400.41M

88.49M

18.14%119.81M

101.42M

Minority profit

14.91%-6.01M

-829.72%-649.24M

---7.06M

426.42%88.97M

-20.00%16.9M

-130.54%-1.44M

777.37%21.13M

--4.73M

-97.34%2.41M

--90.37M

Profit attributable to shareholders

44.38%-139.25M

-307.07%-1.3B

-250.37M

53.87%-319.6M

-282.65%-692.77M

-1,128.88%-861.85M

223.06%379.29M

83.77M

962.11%117.41M

11.05M

Basic earnings per share

47.62%-0.11

-296.30%-1.07

-0.21

55.00%-0.27

-253.85%-0.6

-955.56%-0.77

178.57%0.39

0.09

1,300.00%0.14

0.01

Diluted earnings per share

47.62%-0.11

-296.30%-1.07

-0.21

55.00%-0.27

-253.85%-0.6

-955.56%-0.77

178.57%0.39

0.09

1,300.00%0.14

0.01

Currency Unit

CNY

Accounting Standards

IAS

Audit Opinions

Unqualified Opinion

Auditor

Ernst & Young

	(Q6)Jun 30, 2024	(FY)Dec 31, 2023	(Q6)Jun 30, 2023	(FY)Dec 31, 2022	(FY)Dec 31, 2021	(Q6)Jun 30, 2021	(FY)Dec 31, 2020	(Q6)Jun 30, 2020	(FY)Dec 31, 2019	(FY)Dec 31, 2018
Turnover	-0.61%537.18M	-6.06%1.19B	--540.47M	-19.49%1.26B	-4.14%1.57B	26.53%672.56M	72.12%1.64B	--531.56M	-14.36%951.65M	--1.11B
Operating income	-0.61%537.18M	-6.06%1.19B	540.47M	-19.49%1.26B	-4.14%1.57B	26.53%672.56M	72.12%1.64B	531.56M	-14.36%951.65M	1.11B
Cost of sales	-38.09%-148.89M	-21.17%-286.45M	---107.82M	14.17%-236.41M	2.98%-275.43M	-16.74%-124.08M	-29.74%-283.88M	---106.29M	10.69%-218.8M	---244.98M
Operating expenses	-38.09%-148.89M	-21.17%-286.45M	-107.82M	14.17%-236.41M	2.98%-275.43M	-16.74%-124.08M	-29.74%-283.88M	-106.29M	10.69%-218.8M	-244.98M
Gross profit	-10.25%388.29M	-12.32%901.02M	432.65M	-20.63%1.03B	-4.39%1.29B	28.97%548.48M	84.77%1.35B	425.27M	-15.39%732.85M	866.19M
Selling expenses	-3.26%-232.24M	-0.17%-494M	---224.9M	-7.18%-493.17M	13.71%-460.11M	-29.33%-228.83M	-61.59%-533.25M	---176.94M	30.48%-330.01M	---474.71M
Administrative expenses	-7.35%-124.16M	43.59%-254.29M	---115.66M	61.41%-450.76M	-487.82%-1.17B	-1,049.55%-1.03B	-26.41%-198.7M	---89.23M	16.48%-157.18M	---188.19M
Research and development expenses	57.32%-170.11M	-27.20%-636.4M	---398.53M	-62.78%-500.31M	-94.82%-307.35M	-202.11%-139.61M	-59.54%-157.76M	---46.21M	-76.10%-98.89M	---56.15M
Impairment and provision	-5.10%-3.86M	-6,473.38%-1.79B	---3.67M	-241.00%-27.22M	-866.22%-7.98M	-64.36%-2.5M	-139.28%-826K	---1.52M	117.82%2.1M	---11.8M
-Impairment of intangible assets	----	---1.51B	----	----	----	----	----	----	----	----
-Impairment of property, machinery and equipment	----	---61.09M	----	----	----	----	----	----	----	----
-Goodwill impairment	----	---211.44M	----	----	----	----	----	----	----	----
-Other impairment is provision	-5.10%-3.86M	84.64%-4.18M	---3.67M	-241.00%-27.22M	-866.22%-7.98M	-64.36%-2.5M	-139.28%-826K	---1.52M	117.82%2.1M	---11.8M
Special items of operating profit	-34.15%12.77M	29.69%45.8M	--19.39M	-33.02%35.32M	38.49%52.73M	126.16%25.09M	103.92%38.07M	--11.09M	50.19%18.67M	--12.43M
Operating profit	55.52%-129.31M	-445.16%-2.23B	-290.72M	31.46%-408.47M	-218.81%-596M	-772.10%-823.11M	199.40%501.63M	122.47M	13.38%167.54M	147.77M
Financing cost	-56.60%-30M	-70.60%-43.83M	---19.16M	-140.05%-25.69M	32.01%-10.7M	46.05%-5.41M	-46.01%-15.74M	---10.04M	-47.28%-10.78M	---7.32M
Earning before tax	48.59%-159.31M	-422.99%-2.27B	-309.88M	28.44%-434.17M	-224.87%-606.7M	-836.91%-828.53M	209.95%485.89M	112.43M	11.61%156.76M	140.45M
Tax	-73.22%14.05M	57.42%320.4M	--52.45M	394.25%203.54M	19.07%-69.17M	-45.23%-34.77M	-131.34%-85.47M	---23.94M	5.34%-36.95M	---39.03M
After-tax profit from continuing operations	43.57%-145.26M	-745.61%-1.95B	-257.43M	65.88%-230.63M	-268.79%-675.87M	-1,075.54%-863.29M	234.20%400.41M	88.49M	18.14%119.81M	101.42M
Earning after tax	43.57%-145.26M	-745.61%-1.95B	-257.43M	65.88%-230.63M	-268.79%-675.87M	-1,075.54%-863.29M	234.20%400.41M	88.49M	18.14%119.81M	101.42M
Minority profit	14.91%-6.01M	-829.72%-649.24M	---7.06M	426.42%88.97M	-20.00%16.9M	-130.54%-1.44M	777.37%21.13M	--4.73M	-97.34%2.41M	--90.37M
Profit attributable to shareholders	44.38%-139.25M	-307.07%-1.3B	-250.37M	53.87%-319.6M	-282.65%-692.77M	-1,128.88%-861.85M	223.06%379.29M	83.77M	962.11%117.41M	11.05M
Basic earnings per share	47.62%-0.11	-296.30%-1.07	-0.21	55.00%-0.27	-253.85%-0.6	-955.56%-0.77	178.57%0.39	0.09	1,300.00%0.14	0.01
Diluted earnings per share	47.62%-0.11	-296.30%-1.07	-0.21	55.00%-0.27	-253.85%-0.6	-955.56%-0.77	178.57%0.39	0.09	1,300.00%0.14	0.01
Currency Unit	CNY	CNY	CNY	CNY	CNY	CNY	CNY	CNY	CNY	CNY
Accounting Standards	IAS	IAS	IAS	IAS	IAS	IAS	IAS	IAS	IAS	IAS
Audit Opinions	--	Unqualified Opinion	--	Unqualified Opinion	Unqualified Opinion	--	Unqualified Opinion	--	Unqualified Opinion	Unqualified Opinion
Auditor	--	Ernst & Young	--	Ernst & Young	Ernst & Young	--	Ernst & Young	--	Ernst & Young	Ernst & Young

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data

06660 AIM VACCINE

AIM VACCINE Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Analysis

Analyst Rating

Price Target